Search Results - oppenheim

2 Results

Sort By:

Therapeutic Antitumor Combination Containing TLR4 Agonist HMGN1

Abstract: Immune checkpoint inhibitors (e.g. CTLA-4, PD-L1) have recently shown significant promise in the treatment of cancer. However, when used alone, these checkpoint inhibitors are limited by the absence or repression of immune cells within the targeted cancer. For those cancers associated with these limited immune systems, there remains a need...

Published: 4/22/2025 | Inventor(s): Joost Oppenheim, De Yang, Michael Bustin

Keywords(s): Alarmin, Checkpoint Inhibitor, CTLA-4, HMGN1, Immunooncology, Oppenheim, TLR4, TLR7/8

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics

Fully Human Antibody Targeting Tumor Necrosis Factor Receptor Type 2 (TNFR2) for Cancer Immunotherapy

Abstract: Tumor necrosis factor receptor type 2 (TNFR2)-expressing regulatory T cells (Tregs), present in the tumor microenvironment, play an important role in tumor immune evasion. TNFR2 plays a crucial role in stimulating the activation and proliferation of Tregs, a major checkpoint of antitumor immune responses. In addition to its expression on Tregs,...

Published: 4/22/2025 | Inventor(s): Joost Oppenheim, Dimiter Dimitrov, De Yang, Xin Chen, Zhongyu Zhu

Keywords(s): ADCC, ANTIBODY, Antibody-dependent Cellular Cytotoxicity, CANCER, Immunotherapy, Oppenheim, TNFR2, Tregs, Tumor Necrosis Factor Receptor Type 2

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology